<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14811">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687608</url>
  </required_header>
  <id_info>
    <org_study_id>AskBio009-101</org_study_id>
    <nct_id>NCT01687608</nct_id>
  </id_info>
  <brief_title>Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B</brief_title>
  <official_title>A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Biopharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asklepios Biopharmaceutical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of single ascending IV doses of a Factor
      IX (FIX) Gene Therapy in up to 16 Adults with Hemophilia B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia B is a genetic X-linked bleeding disorder caused by a deficiency in
      blood-clotting Factor IX (FIX) activity. FIX is synthesized in the liver and circulates in
      the blood as a proenzyme. Current treatment for hemophilia B is based on replacement of the
      deficient FIX with IV injections of recombinant FIX protein prophylactically or as needed to
      treat bleeding episodes. This clinical program will test a gene transfer approach involving
      the use of a gene delivery vector carrying a FIX gene. This first-in-humans study is
      intended to evaluate the safety, kinetics, and if possible, the dose of AskBio009 required
      to achieve stable plasma FIX activity between 10% and 40% of normal activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2029</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients experiencing treatment-related adverse events by dose group</measure>
    <time_frame>Infusion to Week 3 and Infusion to end of study</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory evaluations</measure>
    <time_frame>Change from baseline at week 3 and change from baseline at the end of study</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in FIX activity levels, FIX protein levels, and Bleeding Episode Severity &amp; Frequency</measure>
    <time_frame>At multiple timepoints from pre-dose through up to 5 years post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response to AskBio009</measure>
    <time_frame>At multiple timepoints from pre-dose through up to 5 years post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of AskBio009 genomes in blood, saliva, urine, stool, and semen</measure>
    <time_frame>At multiple timepoints from pre-dose through up to 1 years post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>AskBio009 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AskBio009</intervention_name>
    <description>Single dose IV injection</description>
    <arm_group_label>AskBio009 Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18-75 years, inclusive

          -  Established hemophilia B with ≥3 hemorrhages per year requiring treatment with
             exogenous FIX OR use of FIX prophylaxis because of history of frequent bleeding
             episodes

          -  Plasma FIX activity ≤2% (&lt;1% for first cohort; then per protocol)

          -  Negative for active Hepatitis C virus (HCV), defined as Hepatitis C virus antibody
             negative and negative (undetectable) PCR test for plasma Hepatitis C virus
             ribonucleic acid (RNA) OR if Hepatitis C virus antibody positive must have ≥2
             consecutive negative (undetectable) PCR tests for plasma HCV RNA at least 3 months
             apart, and negative at screening

        Exclusion Criteria:

          -  Family history of inhibitor to FIX protein or personal laboratory evidence of having
             developed inhibitors to FIX protein at any time (&gt;0.6 Bethesda Units on any single
             test)

          -  Documented prior allergic reaction to any FIX product

          -  Detectable AAV8 neutralizing antibodies

          -  Markers of hepatic inflammation or overt or occult cirrhosis as evidenced by one or
             more of the following:

               -  Platelet count &lt;175,000/μL

               -  Albumin ≤3.5 g/dL

               -  Total bilirubin &gt;1.5 x ULN and direct bilirubin ≥0.5 mg/dL

               -  Alkaline phosphatase &gt;2.0 x ULN

               -  ALT or AST &gt;2.0 x ULN (except for subjects who are HIV infected)

               -  Liver biopsy in the past indicating moderate or severe fibrosis (Metavir staging
                  of 2 or greater)

               -  History of ascites, varices, variceal hemorrhage or hepatic encephalopathy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott WJ McPhee, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Biopharmaceutical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott WJ McPhee, PhD, MPH</last_name>
    <phone>919-968-2727</phone>
    <email>patient_information@askbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hemophilia Treatment Center at Orthopaedic Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Quon, MD</last_name>
      <phone>213-742-1402</phone>
      <email>dquon@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Lacanilao</last_name>
      <phone>213-742-1407</phone>
      <email>LLacanilao@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Doris Quon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Young, MD</last_name>
      <phone>323-361-5507</phone>
      <email>gyoung@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Geraldine Pira</last_name>
      <phone>323-361-5505</phone>
      <email>gpira@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricel Miguelino, MD</last_name>
      <phone>916-734-7633</phone>
      <email>maricel.miguelino@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Luu, PhD</last_name>
      <phone>916-734-3746</phone>
      <email>tluu@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jerry S Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette von Drygalski, MD</last_name>
      <phone>619-471-0335</phone>
      <email>avondrygalski@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas J. Cramer, PhD</last_name>
      <phone>619-471-0421</phone>
      <email>tcramer@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Annette von Drygalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U of Colorado School of Medicine, Hemophilia &amp; Thrombosis Treatment Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylin Manco-Johnson, MD</last_name>
      <phone>303-724-0365</phone>
      <email>Marilyn.Manco-Johnson@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marylin Manco-Johnson, MD</last_name>
      <phone>303-724-0363</phone>
    </contact_backup>
    <investigator>
      <last_name>Marylin Manco-Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kesley D Tyson, MS</last_name>
      <phone>404-785-9856</phone>
      <email>kdtyson@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Yandell</last_name>
      <phone>404-785-4677</phone>
      <email>byandel@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Kempton, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Howard</last_name>
      <phone>312-942-7902</phone>
      <email>rosie_howard@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Craig</last_name>
      <phone>312-563-2715</phone>
      <email>erin_craig@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa N Boggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Division of Hematology, Oncology, &amp; Transplantation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joni Osip, RN</last_name>
      <phone>612-625-1110</phone>
      <email>JOSIP1@fairview.org</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Quinton, RN,BSN,CCRC</last_name>
      <phone>612-626-1421</phone>
      <email>quint003@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Reding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Walsh, MD</last_name>
      <phone>212-241-3443</phone>
      <email>christopher.walsh@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Johanna McCarthy</last_name>
      <phone>212-241-8303</phone>
      <email>johanna.mccarthy@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher E Walsh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hemophilia Center, Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Lattimore, RN</last_name>
      <phone>503-418-4495</phone>
      <email>lattimo@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Beach, RN</last_name>
      <phone>530-494-7425</phone>
      <email>beachk@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Recht, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia and Thrombosis Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Escobar, MD</last_name>
      <phone>713-500-8630</phone>
      <email>miguel.escobar@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Madeline Cantini</last_name>
      <phone>713-500-8352</phone>
      <email>madeline.cantini@uth.tm</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Konkle, MD</last_name>
      <phone>206-233-3349</phone>
      <email>barbarak@psbc.org</email>
    </contact>
    <contact_backup>
      <last_name>Steve Grantham, CRC</last_name>
      <phone>206-398-5929</phone>
      <email>SteveG@psbc.org.org</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara A Konkle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.askbio.com/patientinfo.html</url>
    <description>Click here for more information about this Phase I/II Hemophilia B Gene Transfer Trial</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia B</keyword>
  <keyword>factor IX deficiency</keyword>
  <keyword>gene therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
